Gunka Igor, Dostalik Jan, Martinek Lubomir, Gunkova Petra, Mazur Miloslav
Department of Surgical Studies, Faculty of Medicine, University of Ostrava, Dvorakova 7, Ostrava, 701 03 Czech Republic ; Department of Surgery, University Hospital Ostrava, 17. listopadu 1790, Ostrava - Poruba, 708 52 Czech Republic.
Indian J Surg. 2013 Apr;75(2):94-101. doi: 10.1007/s12262-012-0427-6. Epub 2012 Mar 16.
The aim of our study was to evaluate the prognostic significance of blood transfusion on recurrence and survival in patients undergoing curative resections for colorectal cancer. Retrospective analysis of prospectively collected data of patients after elective resections for colorectal cancer between January 2001 and December 2009 was undertaken. The main endpoint was overall survival, disease-free survival, and recurrence rate. These data were evaluated in relation to blood transfusion (group A, no blood transfusion; group B, one to two blood transfusions; group C, three and more blood transfusions). A total of 583 patients met the criteria for inclusion in the study. Of these, 132 (22.6 %) patients received blood transfusion in the perioperative period. There were 83 (14.2 %) patients who received one or two blood transfusions and 49 (8.4 %) patients who required three or more transfusions. Patients with three or more transfusions had a significantly worse 5-year overall survival, disease-free survival, and increased incidence of distant recurrences in comparison with the group without transfusion or the group with one or two transfusions. Multivariate analysis showed that the application of three or more blood transfusions is an independent risk factor for overall survival (P = 0.001; HR 2.158; 95 % CI 1.370-3.398), disease-free survival (P < 0.001; HR 2.514; 95 % CI 1.648-3.836), and the incidence of distant recurrence (P < 0.001; HR 2.902; 95 % CI 1.616-5.212). Application of three or more blood transfusions in patients operated for colorectal carcinoma is an adverse prognostic factor. Indications for blood transfusion should be carefully considered not only with regard to the risk of early complications, but also because of the possibility of compromising long-term results.
我们研究的目的是评估输血对接受结直肠癌根治性切除术患者复发和生存的预后意义。对2001年1月至2009年12月期间接受择期结直肠癌切除术后患者的前瞻性收集数据进行回顾性分析。主要终点是总生存期、无病生存期和复发率。这些数据根据输血情况进行评估(A组,未输血;B组,一至两次输血;C组,三次及以上输血)。共有583例患者符合纳入本研究的标准。其中,132例(22.6%)患者在围手术期接受了输血。83例(14.2%)患者接受了一或两次输血,49例(8.4%)患者需要三次及以上输血。与未输血组或接受一或两次输血组相比,接受三次及以上输血的患者5年总生存期、无病生存期明显更差,远处复发发生率更高。多因素分析显示,三次及以上输血的应用是总生存期(P = 0.001;HR 2.158;95% CI 1.370 - 3.398)、无病生存期(P < 0.001;HR 2.514;95% CI 1.648 - 3.836)和远处复发发生率(P < 0.001;HR 2.902;95% CI 1.616 - 5.212)的独立危险因素。对结直肠癌手术患者应用三次及以上输血是一个不良预后因素。输血指征不仅应在考虑早期并发症风险时仔细权衡,还应考虑到可能影响长期预后的可能性。